# BOND-003

Source: https://onco.cc/trials/bond-003/  
OnCo record `bond-003` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A cancer-killing virus instilled into the bladder produced complete responses in three quarters of patients whose BCG had failed, with almost no serious side effects.

## Summary

BOND-003, trial NCT04452591 sponsored by CG Oncology and reported in 2024 with publication in Lancet Oncology in 2025, showed that a cancer-killing virus instilled into the bladder produced complete responses in three quarters of patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer with carcinoma in situ, with almost no serious side effects. In the single-arm cohort C of 110 patients, complete response at any time was 75.2 percent and 41.8 percent at 24 months, with no severe treatment-related events, and a rolling licence application is under way in 2026. OnCo links it to bladder cancer, oncolytic viruses, cretostimogene grenadenorepvec and the BCG-unresponsive term. It is a single-arm registrational study, with the randomised PIVOT-006 and CORE-008 ongoing, so durability against comparators is the open question.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-07
- Registry id: NCT04452591
- Phase: 3
- Setting: BCG-unresponsive high-risk NMIBC with CIS: intravesical cretostimogene grenadenorepvec, single arm (cohort C)
- Sponsor: CG Oncology
- Enrolled: 110
- Result: CR 75.2%; 24-month CR 41.8%.
- Outcomes: Complete response at any time: Cretostimogene 75.2%; Complete response at 24 months: Cretostimogene 41.8%
- Replication: Single-arm registrational; PIVOT-006 (intermediate-risk, randomised) and CORE-008 (BCG-naive) ongoing.

## Sources

- ClinicalTrials.gov NCT04452591: https://clinicaltrials.gov/study/NCT04452591

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- technologies: [Oncolytic viruses](https://onco.cc/technologies/oncolytic-virus/)
- drugs: [Cretostimogene grenadenorepvec](https://onco.cc/drugs/cretostimogene/)
- companies: [CG Oncology](https://onco.cc/companies/cg-oncology/)
- terms: [BCG-unresponsive](https://onco.cc/terms/bcg-unresponsive/)

---
JSON: https://onco.cc/api/v1/entities/bond-003.json